Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran Biomed J. 2023 Jul 1;27(4):167-72. doi: 10.61186/ibj.3923.
Liver transplantation and surgical resection are two major strategies for treatment of hepatocellular carcinoma (HCC) patients. One approach to treating HCC is the suppression of metastasis to other tissues. Herein, we aimed to study the effect of miR-4270 inhibitor on migration of HepG2 cells as well as activity of matrix metalloproteinase (MMP) these cells in order to find a strategy to suppress metastasis in future.
HepG2 cells were treated with 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 nM of miR-4270 inhibitor, and then the cell viability was measured by trypan blue staining. Afterwards, cell migration and MMP activity of HepG2 cells were assessed by wound healing assay and zymography, respectively. The MMP gene expression was determined by real-time reverse transcription polymerase chain reaction.
Results showed that miR-4270 inhibitor decreased the cell viability of HepG2 cells in a concentration-dependent manner. Also, inhibition of the miR-4270 reduced invasion, MMP activity, and expression of MMP genes in HepG2 cells, respectively.
Our findings suggest that miR-4270 inhibitor decreases in vitro migration, which could help find a new approach for HCC therapy patients.
肝移植和手术切除是治疗肝细胞癌（HCC）患者的两种主要策略。治疗 HCC 的一种方法是抑制其向其他组织转移。在此，我们旨在研究 miR-4270 抑制剂对 HepG2 细胞迁移以及这些细胞基质金属蛋白酶（MMP）活性的影响，以期为未来的转移抑制寻找策略。
用 0、10、20、30、40、50、60、70、80 和 90 nM 的 miR-4270 抑制剂处理 HepG2 细胞，然后用台盼蓝染色法测量细胞活力。之后，通过划痕愈合试验评估 HepG2 细胞的迁移和 MMP 活性，通过实时逆转录聚合酶链反应确定 MMP 基因表达。
结果表明，miR-4270 抑制剂呈浓度依赖性降低 HepG2 细胞的活力。此外，miR-4270 的抑制分别降低了 HepG2 细胞的侵袭、MMP 活性和 MMP 基因的表达。
我们的研究结果表明，miR-4270 抑制剂可降低 HepG2 细胞的体外迁移能力，这可能有助于为 HCC 治疗患者找到新的治疗方法。
